$NEO Rose 4.1% After Medicare Expanded RaDaR ST Coverage

NeoGenomics (NASDAQ: NEO) shares rose 4.1% on Aug 26, 2026 after the company said Medicare expanded coverage for its RaDaR ST molecular residual disease (MRD) test to include immunotherapy monitoring in late-stage solid tumors.

What NeoGenomics announced

NeoGenomics said its RaDaR ST MRD assay received expanded coverage from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX). The company pointed to coverage under the MolDX local coverage determination for plasma-based genomic profiling in solid tumors (LCD L38043). The expansion adds use of the test for monitoring response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.

In plain English: the company is saying Medicare will cover more ways doctors can use its blood-based tumor DNA testing—specifically, tracking how patients are responding to certain immunotherapies.

What it means for NeoGenomics

Expanded Medicare coverage can matter because it can reduce reimbursement uncertainty for clinicians and labs, which could support broader adoption in real-world care. By adding immunotherapy response monitoring in late-stage solid tumors, the announcement positions RaDaR ST as a tool not just for detecting residual disease, but also for following patients over time during treatment.

For NeoGenomics, that could widen the set of clinical scenarios where RaDaR ST is ordered, potentially increasing utilization if physicians incorporate serial monitoring into care pathways. It also reinforces the company’s push into liquid biopsy and MRD testing, where coverage decisions often influence how quickly a test moves from “interesting” to routine.

How the stock reacted

NEO traded higher across the session, finishing up 4.1% on Aug 26, 2026.

Window	Move
5 min	+0.2%
10 min	+0.8%
30 min	+1.0%
1 hour	+0.8%
end of day	+4.1%

On a market-adjusted basis, the stock’s same-day excess move versus the SPY was +3.8%.